Dabigatran
- Generic Name
- Dabigatran
- Brand Names
- Dabigatran Etexilate Leon Farma, Dabigatran Etexilate Accord, Pradaxa
- Drug Type
- Small Molecule
- Chemical Formula
- C25H25N7O3
- CAS Number
- 211914-51-1
- Unique Ingredient Identifier
- I0VM4M70GC
- Background
Dabigatran is the active form of the orally bioavailable prodrug dabigatran etexilate.
Drug Interaction Study of Simvastatin and Dabigatran
- First Posted Date
- 2018-11-01
- Last Posted Date
- 2019-03-12
- Lead Sponsor
- Korea University Guro Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT03728101
- Locations
- 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of
A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients.
- Conditions
- Non-valvular Atrial Fibrillation
- Interventions
- First Posted Date
- 2018-10-23
- Last Posted Date
- 2020-12-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 70000
- Registration Number
- NCT03715725
- Locations
- 🇳🇴
Many Locations, Multiple Locations, Norway
Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in Korea
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2018-06-28
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 64684
- Registration Number
- NCT03572972
- Locations
- 🇰🇷
Korea University Hospital, Seoul, Korea, Republic of
Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs DOACs)
- Conditions
- Major BleedAtrial FibrillationIschemic StrokeSystemic EmbolizationAll-cause MortalityMyocardial Infarction
- Interventions
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2021-01-08
- Lead Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
- Target Recruit Count
- 227579
- Registration Number
- NCT03568916
- Locations
- 🇨🇦
Centre de recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, Quebec, Canada
Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).
- Conditions
- Left Atrial Appendage ThrombosisWatchman LAA Closure DeviceAtrial FibrillationDevice Related Thrombus
- Interventions
- First Posted Date
- 2018-05-29
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT03539055
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Dabigatran Versus Warfarin With NVAF Who Undergo PCI
- Conditions
- Coronary Artery DiseaseAtrial Fibrillation
- Interventions
- First Posted Date
- 2018-05-24
- Last Posted Date
- 2019-01-04
- Lead Sponsor
- Shenyang Northern Hospital
- Target Recruit Count
- 1120
- Registration Number
- NCT03536611
- Locations
- 🇨🇳
General Hospital of Northern Theater Command, Shenyang, Liaoning, China
Clinical Trial to Assess the Safety and Pharmacokinetics of RDG-17012 Capsule and Pradaxa® Capsule in Healthy Male Volunteers
- Conditions
- Healthy
- Interventions
- Drug: RDG-17012 Capsule
- First Posted Date
- 2018-04-12
- Last Posted Date
- 2018-04-12
- Lead Sponsor
- Huons Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT03495739
- Locations
- 🇰🇷
Huons, Gyeonggi-do, Seongnam-si, Korea, Republic of
Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy
- Conditions
- Atrial Fibrillation
- Interventions
- Device: CE-mark approved LAA closure devices
- First Posted Date
- 2018-03-13
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 912
- Registration Number
- NCT03463317
- Locations
- 🇩🇪
Klinikum Herford, Med. Klinik III/ Kardiologie, Herford, Germany
🇩🇪Westpfalz-Klinikum GmbH, Klinik für Innere Medizin II - Kardiologie, Kaiserslautern, Germany
🇩🇪UKSH - Campus Kiel, Medizinische Klinik III - Kardiologie, Angiologie, Intensivmedizin, Kiel, Germany
Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf)
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 51690
- Registration Number
- NCT03441633
- Locations
- 🇪🇸
IDIAP Jordi Gol, Barcelona, Cataluña, Spain
Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386)
- Conditions
- Renal Insufficiency
- Interventions
- First Posted Date
- 2017-10-17
- Last Posted Date
- 2020-01-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 32
- Registration Number
- NCT03311841
- Locations
- 🇺🇸
Clinical Pharmacology of Miami ( Site 0001), Hialeah, Florida, United States
🇺🇸Orlando Clinical Research Center ( Site 0002), Orlando, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.